KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Non-Current Deferred Tax Liability (2016 - 2026)

Gsk has reported Non-Current Deferred Tax Liability over the past 18 years, most recently at -$393.7 million for Q1 2026.

  • For Q1 2026, Non-Current Deferred Tax Liability rose 22.63% year-over-year to -$393.7 million; the TTM value through Mar 2026 reached -$393.7 million, up 22.63%, while the annual FY2025 figure was -$387.1 million, 178.95% down from the prior year.
  • Non-Current Deferred Tax Liability for Q1 2026 was -$393.7 million at Gsk, down from -$387.1 million in the prior quarter.
  • Over five years, Non-Current Deferred Tax Liability peaked at $490.3 million in Q4 2024 and troughed at -$4.7 billion in Q1 2022.
  • A 5-year average of -$528.8 million and a median of -$387.1 million in 2025 define the central range for Non-Current Deferred Tax Liability.
  • Biggest five-year swings in Non-Current Deferred Tax Liability: skyrocketed 96.26% in 2022 and later tumbled 233.45% in 2023.
  • Year by year, Non-Current Deferred Tax Liability stood at $339.0 million in 2022, then rose by 13.87% to $386.0 million in 2023, then increased by 27.02% to $490.3 million in 2024, then plummeted by 178.95% to -$387.1 million in 2025, then decreased by 1.7% to -$393.7 million in 2026.
  • Business Quant data shows Non-Current Deferred Tax Liability for GSK at -$393.7 million in Q1 2026, -$387.1 million in Q4 2025, and -$526.3 million in Q3 2025.